Due to the high genetic heterogeneity of hearing loss (HL), current clinical testing includes sequencing large numbers of genes, which often yields a significant number of novel variants.
INTRODUCTION
Sensorineural hearing loss (SNHL) is the most common congenital sensory deficit, with an estimated prevalence of 2-3 cases per 1,000 individuals (Morton & Nance, 2006) . Approximately half of SNHL in children is due to genetic causes, with 70% being nonsyndromic and 30% syndromic (Marazita et al., 1993; Smith, Bale, & White, 2005) . Although variation in the GJB2 gene is the most common cause of nonsyndromic genetic SNHL in many populations, there is high genetic and allelic heterogeneity, with over 100 implicated genes (Hereditary Hearing Loss Homepage: https://hereditaryhearingloss.org) (Abou Tayoun et al., 2016; Alford et al., 2014) .
Given the substantial genetic contribution to SNHL, a clinical genetics evaluation, including comprehensive sequencing, is recommended as part of a standard of care diagnostic work-up. Results of genetic testing can inform clinical management, particularly if a genetic syndrome is identified before the onset of additional clinical manifestations (Alford et al., 2014) . The interpretation of sequence variants is a critical component of an accurate genetic diagnosis, and discrepancies in variant interpretation and classification have been well-documented and can have serious implications for patient care (Amendola et al., 2016; Booth et al., 2015; Harrison et al., 2017) . The large number of genes sequenced during hearing loss (HL) genetic testing routinely yields a large number of novel variants, imposing a significant interpretation challenge. Illustrating the extent of discrepancies in variant interpretation, as of December 4, 2018, 257 (8.1%) of the 3,162 sequence variants in the nine major HL genes represented in our variant pilot (USH2A, GJB2, SLC26A4, MYO7A, KCNQ4, TECTA, MYO6, COCH, and CDH23) had conflicting interpretations in ClinVar.
In an effort to foster accurate interpretation and to reduce discrepancies across laboratories, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published recommendations and guidelines for the interpretation of sequence variants (Richards et al., 2015) . The ACMG/AMP guidelines contain several types of evidence that are weighted and categorized. Although these guidelines were intended to be used universally for all Mendelian disorders, certain criteria require gene-or disease-specific knowledge, a lack of which has been shown to contribute to discrepancies in variant interpretation (Pepin et al., 2016) . In response to these issues, the National Institute of Health (NIH) Here, we document the work of the Hearing Loss Variant Curation Expert Panel, hereafter referred to as the HL-EP. We adapted the ACMG/AMP guidelines for variant interpretation in the context of HL.
These specified rules were developed using the most common genes and syndromes that contribute to genetic HL, with the intent that most specifications could be used broadly across the many associated genes.
These HL-specific guidelines will be used in the future by the HL-EP to submit variant interpretations to ClinVar as an "expert panel" submitter, with the goal of resolving discrepancies, moving VUS (variants classified as uncertain significance) toward Benign or Pathogenic and increasing the confidence in HL variant classifications in ClinVar.
MATERIALS AND METHODS

Hearing Loss Clinical Domain Working Groups
approval from all members. Upon specifying the ACMG/AMP rules, conference calls and email correspondence were used for the variant pilot using a set of 51 variants from nine common HL genes that represent the varied inheritance patterns, evidence types, and phenotypic spectrum seen across HL cohorts (see Variant Pilot methods below).
The final set of specified rules is shown in Table 1 .
Pathogenic allele frequency for recessive HL
The frequencies of the most common pathogenic variants in HL were determined using a cohort of 3,673 patients tested at the LMM. The three most common sequence variants were NM_004004.5:c.35delG (p.Gly12Valfs), NM_004004.5:c.109G>A
(p.Val37Ile), and NM_004004.5:c.101T>C (p.Met34Thr) in GJB2, while the fourth variant was NM_206933.2:c.2299delG (p.Glu767Serfs) in the USH2A gene (Table 2) . Test-based cohorts for the GJB2 (n = 1,375 probands) or USH2A (n = 1,887 probands) genes were used to calculate the disease population allele frequency of each one of those variants.
The allele frequencies were confirmed using another HL cohort (n = 2,066) tested at the MORL (Iowa City, IA). Although their frequencies were slightly different, the rankings of the four most common pathogenic variants were recapitulated in this cohort ( Table 2 ). The frequency differences can be attributed to the fact that the MORL cohort excluded patients with positive findings upon GJB2 prescreening.
Therefore, the higher allele frequency (from the LMM) for each variant was conservatively used in calculating BA1 and BS1 for recessive HL.
Our calculations were made under the assumption of Hardy-Weinberg equilibrium and can be obtained using a recently published web application (https://www.cardiodb.org/allelefrequencyapp/) (Whiffin et al., 2017 ).
Performance analysis of functional studies
To assess the performance characteristics (sensitivity, specificity, positive predictive value, and negative predictive value) of the functional assays in each of GJB2, SLC26A4, and COCH, the number of true and false variant calls was determined as follows. Variants classified in ClinVar and included in functional assays were reviewed for classification accuracy and then used for informing performance. Pathogenic and likely pathogenic variants that had abnormal assay readout, defined as statistically significant deviation from wild-type variant(s), were labeled as true positives. Normal assay readouts for pathogenic or likely pathogenic variants were considered false negatives. Similarly, benign and likely benign variants with normal assay readouts (i.e., does not significantly deviate from wild-type variants) were counted as true negatives. False positives were benign or likely benign variants with abnormal assay readouts. A summary of true and false variant calls by five functional assays in the above three genes is shown in Supporting Information, Table S1 .
Variant pilot
Following the specification of the ACMG/AMP guidelines, the rules were refined by interpreting a set of 51 variants in GJB2, SLC26A4, Tables 8 and 9 Example: Detected in trans with a pathogenic variant (recessive) (Continues)
TA B L E 1 (Continued)
Pathogenic criteria
Rule
Rule description
PM3_VeryStrong 4 points awarded from Tables 8 and 9 Example: Detected in trans in ≥4 probands with a pathogenic variant (recessive) PM3_Strong 2 points awarded from Tables 8 and 9 Example: Detected in trans in 2 probands with a pathogenic variant (recessive)
PM3_Supporting 0.5 points awarded from Tables 8 and 9Examples 
RESULTS
Summary of specifications
The HL-EP recommended specifications for 21 ACMG/AMP rules ( 
Population data (BA1, BS1, and PM2)
Recessive and dominant forms of HL were distinguished with respect to the interpretation of variant frequency data from the general population. This is mainly due to differences in prevalence, penetrance, and gene contribution. Evidence-based estimates of these attributes are critical for establishing recessive and dominant allele frequency thresholds, at which a benign or pathogenic criterion might be assigned for a given variant. The minor allele frequencies required to apply these criteria are shown in Figure 1 . For this work, the ExAC and gnomAD population databases were used, though other databases with a minimum of 2,000 alleles are also sufficient. Caution should be used if the cutoffs specified below are applied on an uncharacterized population or a population with minimal representation in ExAC or gnomAD. Furthermore, although we used ExAC which was the main general population dataset at the time of this study, we expect these databases to continue to grow (as is the case already in gnomAD), and therefore we encourage curators to use the largest datasets in their filtering frequency calculations. Table   2 ). The higher frequency value for each variant was used to derive a conservative minor allele frequency (MAF) threshold for BA1, BS1, and BS1_Supporting.
Recessive HL
BA1 and BS1
Using the recently published allele frequency web app (https://www.
cardiodb.org/allelefrequencyapp/), the MAF threshold for BA1 was set at ≥ 0.5% for autosomal recessive HL. This was calculated by using a prevalence of 1/200, complete penetrance (100%), and a maximum allelic heterogeneity contribution of 7.2% based on the most common pathogenic variant (NM_004004.5:c.35delG in GJB2; Table 2 ). Genetic heterogeneity was set to 1 given that the 7.2% allele frequency used was derived across all genetic causes of HL. We then reviewed all reportedly pathogenic variants with frequencies near or higher than this threshold and developed a BA1 exclusion list, which includes two low penetrance variants, GJB2 p.Met34Thr and p.Val37Ile, as well as several founder mutations (Supporting Information, Table S2 ). Any variant exceeding 0.5% in any subpopulation, aside from variants on the exclusion list (Supporting Information, Table S2 ), would default to a benign classification. A 95% confidence interval was used to develop the MAF thresholds. Therefore, in practice, we recommend using the filtering allele frequency in ExAC, or for other population databases or new larger datasets, a 95% confidence interval should be applied using the web application referenced above.
The MAF threshold for BS1 was set at ≥ 0.3% for recessive HL. This was calculated by using a maximum allelic heterogeneity of 4.4%, based upon the second most common pathogenic variant, (p.Val37Ile) in GJB2 (Table 2) , while maintaining the same prevalence, penetrance, genetic heterogeneity, and statistical correction used for the recessive BA1 derivation. Variants exceeding this frequency and having no other conflicting evidence for pathogenicity meet the "Likely Benign" classification, provided they are not the exclusion list in Supporting Information, Table S2 .
The BA1 and BS1 cutoffs were validated using an independent approach, where an extensive curation of the literature was performed to estimate disease attributes (prevalence, gene contribution, and pathogenic allele frequencies) of the most common causes of HL (GJB2, SLC26A4, USH2A, and MYO7A) across several ancestral groups globally (Supporting Information, Methods and Tables S3-S6 ). This approach validated the MAF thresholds determined above.
BS1_Supporting, PM2_Supporting, and PM2
To enable broader use of population allele frequencies, we defined supporting strength levels of BS1 and PM2. BS1_Supporting was set at TA B L E 3 Allele frequency cutoffs for dominant and recessive hearing loss disorders Abbreviations: MAF, minor allele frequency; Preval., prevalence; Allelic Het., allelic heterogeneity. a Allelic heterogeneity encompassed both genetic and allelic heterogeneity because allele frequencies were derived from hearing loss cases spanning all genetic etiologies.
a MAF threshold of ≥ 0.07% using the same metrics as BA1 and BS1 (Table 3) , but 1% for the allelic heterogeneity, which is representative of the most common pathogenic variant in the second most common recessive gene in our HL patient cohorts (NM_206933.2:c.2299delG Table 2 ).
PM2 was set by selecting a MAF that was an order of magnitude lower than the BS1_Supporting value. Therefore PM2 for recessive disorders is ≤ 0.007% (Table 3) . Variants with frequencies between 0.07% and 0.007% can be awarded supporting evidence for pathogenicity (PM2_Supporting ; Table 3 ).
Dominant HL
HL prevalence generally increases with age but with decreasing monogenetic contribution (Cunningham & Tucci, 2017) . Most dominant HL forms are postlingual and therefore are more difficult to distinguish from nongenetic forms (Shearer, Hildebrand, & Smith, 1993) . In the dominant HL frequency threshold calculation, we chose prevalence in individuals aged 0-49 years to minimize those affected by age-related HL. This age range is consistent with the age of onset of the major HL genes, including TECTA (Alloisio et al., 1999; Mustapha et al., 1999; Verhoeven et al., 1998) , DFNA5 (Bischoff et al., 2004; Booth, Azaiez, et al., 2018; Van Laer et al., 1998) , COCH (Nagy, Horvath, Trexler, Repassy, & Patthy, 2004; Robertson et al., 1998; Street et al., 2005) , and WFS1 (Eiberg et al., 2006; Fukuoka, Kanda, Ohta, & Usami, 2007; Hogewind et al., 2010) . Based on a National Health and Nutrition Examination Survey (NHANES) study (n = 7,490 patients), 1/15 individuals are expected to have HL by 49 years of age (Lin et al., 2011) . For dominant BA1 derivation, we conservatively assumed that 50% of those individuals have a genetic cause, and calculated a prevalence of 1/30 (Table   3 ). This is a deliberate overestimation given that 50% is the estimated genetic contribution to congenital HL, which is the highest contribution among all age groups, and is therefore expected to be lower in adults.
Due to a lack of published data on dominant HL penetrance, we used an estimated penetrance of 80%, based on the collective research and clinical experience of the HL-EP members. The relative contributions of known genes to dominant forms of HL were also assessed in a cohort of 2,000 patients tested at MORL. Four genes, TECTA, WFS1, KCNQ4, and COL11A2, were the most common accounting for 20%, 13%, 13%, and 7%, respectively, of all dominant pathogenic variants.
Furthermore, among all nonsyndromic dominant genes tested at the LMM (n = 3,076 probands), KCNQ4 contributed the most for a total of four pathogenic and likely pathogenic variants in one proband each.
Therefore, we conservatively assumed the maximum allelic heterogeneity for a dominant HL gene is 25%. Based on these data, we safely estimated that no dominant variant could contribute more than 5% of all HL in the 0-49 year age range. This is based on the assumption that the maximum contribution of one gene would be 20% (TECTA) and the maximum contribution of any one variant to a gene's HL would be 25% (KCNQ4) (i.e., 20% × 25% = 5%). Our literature search also confirmed a maximum allelic heterogeneity of 5% in any given gene (Hildebrand et al., 2011; Iwasa, Nishio, & Usami, 2016; Naito et al., 2013 ).
Using the above conservative estimates, we set the dominant BA1 cutoff at ≥0.1% ( Figure 1 and Table 3 ). To derive the BS1 value, we used a less conservative estimate of dominant prevalence by assuming only 10% of all HL between ages 0-49 years is genetic. Therefore, a prevalence of 1/150 (1/15 × 10%) was used, while keeping all other values as in BA1, leading to a ≥0.02% BS1 cutoff. An allele frequency of an order of magnitude less than this cutoff (i.e., ≤0.002%) was then considered sufficient to be awarded moderate evidence of pathogenicity (PM2 ;   Table 3 ). Again, we recommend using the filtering allele frequency in ExAC or applying a 95% confidence interval in the cardiodb.org allele frequency app when applying these thresholds.
PM2_Supporting and BS1_Supporting thresholds were not created for autosomal dominant HL. This was for several reasons. We could not replicate the model used for the development of recessive thresholds for BA1, BS1, and BS1_Supporting, which was partly based on the allele frequency of common pathogenic variants, as no variants are common causes of dominant HL. The value used for recessive BS1_Supporting was also the basis for the development of recessive PM2 and PM2_Supporting. Without the ability to use allele frequencies of common dominant alleles, we were unable to create MAF thresholds that had significant enough gaps between the different benign and pathogenic criteria. Furthermore, the value for dominant BS1 was set very low at 0.02%, and therefore, the difference of a single allele could have a significant effect on the odds impact (Tavtigian et al., 2018) . Finally, for dominant HL, we do not expect variants to be present in the general population at an appreciable allele frequency as we would for recessive pathogenic variants, even with the potential for decreased or age-related penetrance in the former.
As described above, in setting BA1 and BS1, we lowered the dominant HL penetrance to 80% which, along with the conservative prevalence, allelic and genetic heterogeneity estimates, allows us to account for pathogenic variants with reduced penetrance in the general population.
It is important to note the phenotypic heterogeneity is exhibited by several of the HL genes. Genes known to cause both dominant and recessive forms of HL, such as TECTA, COL11A2, GJB2, and MYO7A, should be treated per the more conservative recessive rules for applying BA1 and BS1 rules because the frequency cutoffs for recessive inheritance are higher than those for dominant. This will help to avoid erroneously misclassifying variants as benign or likely benign.
However, when considering pathogenicity evidence, the PM2 rule that matches the proposed form of HL (dominant vs. recessive) should be used according to the available evidence about the gene, the segregation data, or the family history information for the proband being assessed. For example, the vast majority of variants reported for GJB2
and MYO7A are associated with autosomal recessive HL and Usher syndrome, respectively. Variants causing autosomal dominant HL in either GJB2 or MYO7A are rare in comparison. Therefore, the autosomal recessive MAF threshold should be utilized for the PM2 rule for these genes. However, for genes that do not have a majority of variants associated with one inheritance pattern, such as TECTA and COL11A2, we recommend using the more conservative dominant rules for PM2, unless there is convincing evidence supporting recessive inheritance.
X-linked forms of HL were not specifically addressed by the HL-EP.
However, based on their relative rarity and the fact that most X-linked genes are not strictly recessive or dominant, with carrier females often displaying milder disease, the recessive thresholds for BA1, BS1, and
BS1_Supporting can be applied for both X-linked recessive and Xlinked dominant HL. The HL-EP also specified that PS1 can be applied for DNA variants located at the same nucleotide in the splice consensus sequence as a known pathogenic variant. Based on the most conserved regions known to impact splicing, we defined the splice consensus sequence here as the first base and last three bases of the exon, the -12 through -1 positions in the intron, and the +1 through +6 positions in the intron.
PS4,
The +/-1,2 positions were excluded, given that these positions should be evaluated using PVS1 rules. In addition, splice prediction algorithms must predict a similar or greater effect than the comparator known pathogenic variant.
Computational predictive tools (PP3, BP4, and BP7)
Computational tools are commonly used to inform variant interpretation. For missense variants, the HL-EP recommends using REVEL, a computational tool that combines predictions from commonly used algorithms for missense variants (Ioannidis et al., 2016) . REVEL was selected based on recently published work from members of ClinGen as well as evaluation within the HL-EP and the SVI (Ghosh, Oak, & Plon, 2017) . Furthermore, we recommend specific REVEL scores are reached to apply supportive evidence of pathogenicity (PP3) or supportive evidence of benign (BP4). PP3 can be applied with a REVEL score of ≥0.7, given that 95% of benign variants are excluded at this score (Ioannidis et al., 2016) . BP4 can be applied with a REVEL score of ≤0.15, given that 95% of pathogenic variants are excluded at this score (Ioannidis et al., 2016) . Variants with a REVEL score between 0.15-0.7
will not receive either rule (PP3 or BP4).
The HL-EP recommends using MaxEntScan when assessing potential splicing impacts at the DNA level for missense, silent, and splice consensus sequence variants outside of the canonical ±1 or 2 sites. For variants at the canonical splice sites, PP3 cannot be applied if PVS1 is used (Abou Tayoun et al., this issue).
Computational and predictive data rules with no changes (PM4, BP3, and BP7)
The HL-EP did not further specify the rules pertaining to protein length changing variants (PM4 and BP3). However, the PVS1 flowchart mentioned above should be carefully followed for large in-frame deletions or insertions, particularly those affecting one or more exons. Silent variants with no predicted splicing impact can have BP7 applied, with no specified changes.
FUNCTIONAL DATA
Functional studies (PS3, PS3_Supporting, and BS4_Supporting)
Based on systematic assessment of the literature, the HL-EP determined that no functional assays met a strong level of evidence for or against pathogenicity, except for a variant-specific knock-in mouse model. This is mainly due to the lack of well-established functional assays with enough data to assess their validity in predicting variant pathogenicity in most HL genes. Except for the functional assays in the COCH, GJB2, and SLC26A4 genes described below, a PS3_Supporting or BS3_Supporting can be appropriately used for evaluating variants in other genes not specified here if the assay is well-validated with positive and negative controls and the results are consistent with a known protein function.
GJB2
This gene, which encodes the gap junction protein, connexin 26, is the most common cause of genetic HL and has been well studied. Sev- We searched the literature for variants that were assessed by these two assays, and that were validly classified as pathogenic, likely pathogenic, benign, or likely benign. We then determined the performance characteristics for each assay as described in the methods section and shown in Supporting Information, Table S7 . Because both assays demonstrated a high sensitivity and positive predictive value, the HL-EP recommends using PS3_Moderate for any novel GJB2 variant resulting in a statistically significant decrease or absence of current or dye transfer compared to wild-type run under the same experimental conditions. On the other hand, given the limited number of benign variants used as negative controls (Supporting Information, Table S1 ), the HL-EP was less confident regarding the ability of either assay to accurately predict benign effects, and in such cases, using BS3_Supporting is more appropriate.
It should be noted that in dye diffusion assays, a negative control (e.g., nontransfected or water injected control) should not display dye diffusion. In electrical coupling assays, water injected controls should display negligible currents at all potentials.
SLC26A4
This gene encodes an anion transporter, and its function has been assayed by measuring transport of radioactive anion isotopes (e.g., iodide or chloride) in cells expressing normal or mutant protein subunits (Bizhanova, Chew, Khuon, & Kopp, 2011; Choi, Stewart, et al., 2009; Dossena, Bizhanova, et al., 2011; Gillam et al., 2004; Ishihara et al., 2010; Palos et al., 2008; Reimold et al., 2011; Scott et al., 2000; Yuan et al., 2012) . Alternatively, other groups have used halide-sensitive fluorescent probes to measure anion transport (Cirello et al., 2012; Dossena, Bizhanova, et al., 2011; Dossena, Rodighiero, et al., 2006; Fugazzola et al., 2007; Jang et al., 2014; Pera et al., 2008 Tables S1 and S7 ).
Again, there was a limited number of benign variants to assess the ability of both assays to predict benign effects (Supporting Information, Table S1 ). Furthermore, compared to GJB2, the two assays had lower positive predictive values (Supporting Information, Table S7 ).
Therefore, we recommend using PS3_Supporting or BS3_Supporting if a pathogenic or a benign effect, respectively, was suggested by either assay.
COCH
This gene encodes cochlin, which is normally secreted into the extracellular matrix of the inner ear (Fransen et al., 1999; Robertson et al., 2006; Robertson et al., 1998) Based on the high sensitivity and positive predictive value (Supporting Information, Tables S1 and S7) of these protein assays, we recommend using PS3_Moderate if a variant exhibits an abnormal secretion, dimerization, or localization pattern compared to wild-type protein.
On the other hand, due to a dearth of benign variants tested by these assays, we recommend using only BS3_Supporting if a variant shows a comparable pattern to wild-type cochlin using these protein assays.
No criteria should be applied if multiple assay results do not agree.
Mutational hot spots or functional domains (PM1)
The HL-EP identified one gene, KCNQ4, in the variant pilot set that har- 
SEGREGATION DATA (PP1, PP1_Moderate, PP1_Strong, AND BS4)
Segregation with disease is used as evidence toward pathogenicity, and with an increasing number of segregations, stronger evidence can be applied. Given that segregation evidence is not specific to HL, the HL-EP worked in conjunction with the SVI to develop guidelines that further specify PP1. Three levels of evidence were recommended for both autosomal dominant and autosomal recessive segregations. Each strength level was based upon likelihood ratios of 4:1 (Logarithm of the odds or LOD 0.6), 16:1 (LOD 1.2), and 32:1 (LOD 1.5) to count as supporting, moderate, and strong evidence, respectively (Table 4) . For autosomal recessive segregations, unaffected individuals with equal probability of inheriting the variant(s) in question, typically siblings of a proband, can be taken into account, as shown in Table 5 . Table 5 See Table 5 See Table 5 TA B L E 5 Recommendations for autosomal recessive segregation evidence (PP1) . Different levels of strength are applied to de novo occurrences depending on how many are observed, whether the phenotype is specific, and whether maternity and paternity are confirmed (Tables 6 and 7) . For recessive disorders, identifying a variant in trans with a pathogenic variant on the second allele in an affected individual is considered evidence toward pathogenicity. This was previously defined in the ACMG/AMP guidelines as moderate evidence (PM3; Richards et al., 2015) . However, if the variant under consideration is found in multiple probands with pathogenic variants on the other allele, the strength of that evidence should be considered greater. Therefore, in conjunction with the SVI, we developed a scoring system to account for the number of compound heterozygous and homozygous probands identified with a variant, as shown in Tables 8 and 9 . Each instance that a variant is found in a proband, either in homozygosity or compound heterozygosity with a second variant, is given a specified number of points, and the total points corresponds to the strength of PM3 that can be applied. Other scenarios, such as homozygous variants in consanguineous families, and variants of unknown phase, were also taken into account.
TA B L E 4 Recommendations for PP1 (segregation evidence)
General recommendations
Supporting Moderate Strong
TA B L E 6 Points awarded per de novo occurrence(s)
Points per proband
Furthermore, if a variant has been observed in many probands, each with a different pathogenic variant on the other allele, the likelihood that the variants are in trans is higher even if phasing has not been performed in every case, assuming the gene has been fully sequenced to detect all variants. In these cases, point values can be adjusted based on confidence of in trans occurrence.
BS2: Observation in controls inconsistent with disease penetrance
BS2 can be utilized when a variant is observed in an adult with normal hearing tests when the HL is expected to be fully penetrant from For autosomal dominant HL, the variant would be heterozygous.
TA B L E 8
However, BS2 should not be implemented when variable onset and severity of HL has been associated to the gene in which the variant occurs.
BP2: Observation in trans with a pathogenic variant for dominant disorders or observation of a variant in cis with a pathogenic variant
The identification of a variant in cis with a pathogenic variant is supportive evidence for a benign interpretation. However, caution is recommended for the application of this rule for a case with an in trans observation of a dominant pathogenic variant. Careful assessment should include whether an earlier onset or more severe phenotype is possible, which could be consistent with an in trans pathogenic variant.
PHENOTYPIC DATA (PP4 AND BP5)
The HL-EP developed recommendations for PP4, which, in the ACMG/AMP guideline, was intended as supporting evidence of pathogenicity when the patient's phenotype is highly specific for a single gene. The HL-EP selected a set of syndromes and genes where clinical features in addition to HL are observed in which PP4 can be applied. Isolated HL is not sufficient to apply PP4. The HL-EP applied this rule to HL syndromes if all known causative genes have been sequenced and the detection rate at least doubles when the added clinical feature(s) is present in the proband or one or more prior reported cases (Table 10 ). The rationale for using a doubling is based on a Bayesian model of the ACMG/AMP guideline whereby any supporting piece of evidence is equivalent to a doubling of likelihood (Tavtigian et al., 2018) . The specific clinical features in addition to HL that are required for application of PP4 are shown in Table 10 .
The HL-EP further specified the BP5 rule, which the ACMG/AMP guidelines defined as supporting evidence of benign when a variant is identified in a case with an alternate cause. The HL-EP recommends that for autosomal recessive genes, BP5 is only invoked when the variant is in the homozygous or compound heterozygous state. It is not recommended to be used for heterozygous observations of variants in autosomal recessive genes, given that affected individuals are frequently identified as carriers of other pathogenic recessive variants in genes unrelated to the cause of their HL.
TA B L E 1 0 Recommendations for specification of PP4
Gene Syndrome
Phenotypes observed in proband or prior reported cases required to apply PP4 Sloan-Heggen et al., 2016) 28.5% (2/7 cases, LMM unpublished data)
EYA1, SIX1
Branchio-otorenal syndrome 3 major; 2 major + 2 minor; or 1 major + a 1st degree relative meeting criteria Major: Branchial anomalies, hearing loss/deafness, preauricular pits, and renal anomalies Minor: External ear anomalies, middle ear anomalies, inner ear anomalies, preauricular tags, and other (facial asymmetry and palate abnormalities) (Chang et al., 2004) 0.2% (Sloan-Heggen et al., 2016) 45% Testing must include deletion/duplication analysis (Smith, 1993) OTOF and DFNB59 ANSD Auditory neuropathy spectrum disorder 1% (Sloan-Heggen et al., 2016) 9-50% (Matsunaga et al., 2012; Rodriguez-Ballesteros et al., 2008; Varga et al., 2006) 
MYH9
MYH9-related disorders
Congenital macrothrombocytopenia and platelet macrocytosis (Pecci et al., 2014) Note: Patient must also be tested for DIAPH1 with no DIAPH1 variants identified <0.1% (Sloan-Heggen et al., 2016) >90% (Pecci et al., 2014; Pecci et al., 2008; Savoia & Pecci, 1993) DIAPH1 AD hearing loss with macrothrombocytopenia Macrothrombocytopenia (Neuhaus et al., 2017; Stritt et al., 2016) (Liu, Newton, & Read, 1995) Detection rate is unknown. Rare syndrome, prevalence of 9/100,000 (Pingault, 2015; Pingault et al., 2010) >75% for WS1 and WS3 30% for WS2 50% for WS4 (Pingault et al., 2010) Testing must include deletion/duplication analysis (Continues) 
REMOVED AND NOT APPLICABLE RULES
The HL-EP recommends that PP2 (missense variants in genes with low rate of benign missense variation) and BP1 (missense variants in genes where only LOF variants cause disease) are not used. These are not applicable to any known genes associated with HL. In addition, the HL-EP supports the SVI's decision to remove the two rules pertaining to variant classifications from reputable sources without evidence available (PP5 and BP6) based on the published rationale (Biesecker & Harrison, 2018) .
COMBINING CRITERIA RULES
The HL-EP recommends following the rules for combining criteria as outlined in the ACMG/AMP guidelines, with the addition of two modifications.
First, the HL-EP specified that PVS1 and PM2_Supporting can be combined to reach a variant classification of likely pathogenic. Note that the ACMG/AMP criteria require combining at least one moderate or two supporting criteria with a very strong criteria to reach a likely pathogenic classification. This modification was decided given that the HL-EP adopted the stringent criteria for evaluating predicted LOF variants, as described above under PVS1, such that we feel that rare variants meeting at least PM2_Supporting have at least a 90% chance of being pathogenic. However, this modification is not applicable in dominant HL because the HL-EP did not create a MAF threshold for PM2_Supporting in the dominant form of the disease (see above).
The second HL-EP modification was that variants meeting BS1 with no conflicting evidence can be classified as Likely Benign. This is consistent with approaches taken by the RASopathy and CMP-EPs (Gelb et al., 2018; Kelly et al., 2018) .
Finally, as per the new PVS1 rule recommendation (Abou Tayoun et al., this issue), we recommend against combining PVS1 with PP3 for the canonical ±1 or 2 splice bases given that PP3 is essentially applying predictive assumptions already built into PVS1.
VARIANT PILOT OF THE HL-SPECIFIED RULES
A set of 51 variants in the GJB2, MYO7A, USH2A, CDH23, MYO6, KCNQ4, COCH, TECTA, and SLC26A4 genes were selected to test and refine the above specifications set by the HL-EP. The majority of variants were in GJB2, USH2A, and SLC26A4 (Figure 2 ). These variants were either present in ClinVar, on the exclusion list for BA1 and BS1, in a HL-EP's internal laboratory data, or identified via literature search.
All the major rule types supporting pathogenicity were tested, except for the rules specifying de novo occurrences, which are extremely rare within HL (Figure 3 ). Dual curation was performed, and then consensus Of note, the most commonly utilized rules in our pilot were PM2
and PM3 and their modified strength levels (supporting through very strong; Figure 3 ). PM2 and PM2_Supporting were used almost equally, with PM2 being applied for 14 variants and PM2_Supporting applied for 13 variants. In addition, PM3 or its modified strengths were used for 25 variants. PP1, PP3, PP4, and PVS1 were also commonly utilized.
Pathogenic or likely pathogenic variants, where either BA1 or BS1 was applied, were only for variants listed on our exclusion list. Furthermore, the single variant of uncertain significance that had BS1 applied was the NM_004004.5:c.-22-2A>C variant in GJB2, which had conflicting data.
The number of variants that were classified as benign, likely benign, uncertain, likely pathogenic and pathogenic, as well as the num- In addition, the consensus discussions performed during the variant pilot led to the identification of several rules that required further clarification to ensure proper application, including PP1, PS4, PP3, BP4, and BP1_Supporting. The clarifications were the result of conversation with the HL-EP as a whole, versus an empirical assessment of the variant pilot. A summary of the genes, their associated phenotype(s) and inheritance pattern(s), and gene-specific rules are shown in Table 11 . The list of variants included in the pilot and their classifications and supporting rules are shown in Supporting Information, Table S8 .
DISCUSSION
Specifying the ACMG/AMP guidelines for HL posed unique challenges, which arose from high prevalence, high genetic heterogeneity, and multiple inheritance patterns. Although published specifications exist for cardiomyopathy and RASopathy, these specifications focus on autosomal dominant disorders that typically have pathogenic missense variants as the causal variants. In contrast, HL is frequently autosomal recessive with LOF as the primary disease mechanism, and therefore, the HL-EP specifications addressed and utilized rules that have not been previously refined for more quantitative and nuanced use, including PM3 and PVS1. These rules were some of the most commonly used rules in the variant pilot, particularly for the classification of likely pathogenic and pathogenic variants, and are likely to be frequent among all recessive disorders ( Figure 3 ). As such, these specifications could be applied or serve as a groundwork for other autosomal recessive disorders that rely heavily on biallelic proband observations and predicted LOF variants.
The MAF thresholds for BA1, BS1, and PM2 were some of the most challenging rules to develop for the HL-EP. The MAF thresholds had to meet the "Goldilocks principle." The thresholds for BA1 and BS1 could not be so high that they would never be reached and they could not be so low that they were over-utilized, as either scenario would lead to variant misclassification. MAF thresholds had to be developed separately for recessive and dominant HL, given the different attributes for each form. Furthermore, variants for recessive disorders are often expected to be present in the general population at low frequency, which poses a challenge to setting hard MAF thresholds for recessive HL. Our pilot variant project demonstrated the impact of our new rules on HL variant specification (Figure 4) . We acknowledge that the pilot project is small (n = 51) and the selected variants were biased, as we needed variants to test as many rule specifications as possible. However, we hope that implementation of the HL-EP's specifications will continue to reduce the number of VUS and lead to fewer conflicts within ClinVar. Indeed, the next steps of the HL-EP will be to provide expert classification on many variants in ClinVar prioritizing medically significant conflicting interpretations (P/LP vs. VUS/LB/B) as well as VUS submitted by multiple labs for which aggregation of data might lead to a shift in classification.
The HL-EP expects that these specifications will evolve as they are utilized by diagnostic laboratories, and as more information on the genetic basis of HL is identified, such as additional autosomal dominant loci, adult-onset HL, and founder mutations in under-studied cohorts.
Furthermore, ongoing general refinements to the ACMG/AMP guidelines may be made by the ClinGen SVI, which will need to be addressed. 
